Shareholders Reject 1-for-10,000 Reverse Stock Split at AGM
BDRX sits 19% above its 52-week low of $2.45 on light trading volume (0.1× avg).
Summary
Biodexa Pharmaceuticals' shareholders rejected a proposed 1-for-10,000 reverse stock split at the re-scheduled Annual General Meeting, leaving the company's NASDAQ listing at risk.
Key Events · Corporate Governance and Compliance · BDRX
-
Reverse Stock Split Fails
Shareholders rejected a proposed 1-for-10,000 reverse stock split (Ordinary Resolution 8 and Special Resolution 10) at the re-scheduled Annual General Meeting.
-
NASDAQ Listing Risk Remains
The failure to pass this extreme reverse stock split resolution leaves the company vulnerable to potential delisting from NASDAQ due to its low share price, a concern highlighted in previous filings.
-
Other Resolutions Passed
Ordinary resolutions 1 through 7 passed with majorities ranging from 73% to 94%, indicating approval for other routine corporate matters.
Analysis · BDRX · Life Sciences
Shareholders rejected a proposed 1-for-10,000 reverse stock split, a critical measure previously announced to address the company's low share price. This outcome leaves Biodexa highly vulnerable to potential delisting from NASDAQ, posing a significant threat to its capital market access and future financing capabilities.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 44.7% of the 302 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.26%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDRX was trading at $2.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $2.45 to $66.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.